PMID: 16502486Feb 28, 2006Paper

Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia

Yonsei Medical Journal
Jun Yong ChoiJune Myung Kim

Abstract

Multiple antibiotic resistance threatens successful treatment of Acinetobacter baumannii infections worldwide. Increasing interest in the well-known activity of sulbactam against the genus Acinetobacter has been aroused. The purpose of this study was to compare the outcomes for patients with Acinetobacter bacteremia treated with cefoperazone/sulbactam versus imipenem/cilastatin. Forty-seven patients with Acinetobacter baumannii bacteremia were analyzed through a retrospective review of their medical records for antibiotic therapy and clinical outcome. Thirty-five patients were treated with cefoperazone/sulbactam, and twelve patients with imipenem/cilastatin. The percentage of favorable response after 72 hours was not statistically different between cefoperazone/sulbactam group and imipenem/cilastatin group. The mortality rate was not statistically different, too. Cefoperazone/sulbactam was found to be as useful as imipenem/cilastatin for treating patients with Acinetobacter bacteremia.

References

Nov 1, 1990·The Journal of Antimicrobial Chemotherapy·Y Obana, T Nishino
Jan 1, 1990·Diagnostic Microbiology and Infectious Disease·C C KnappJ A Washington
Jul 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G M EliopoulosR C Moellering
Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Jun 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M CisnerosA R Cobacho
Apr 1, 1996·Clinical Microbiology Reviews·E Bergogne-Bérézin, K J Towner
Aug 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A S LevinS F Costa
Mar 27, 2001·The Journal of Antimicrobial Chemotherapy·M J Rodríguez-HernándezJ Pachón
May 16, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A S Levin
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Christopher WoodBradley A Boucher
Nov 26, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M Cisneros, J Rodríguez-Baño
May 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carl UrbanJames J Rahal
Sep 3, 2004·Yonsei Medical Journal·Kyungwon LeeUNKNOWN Korean Natiowide Surveillance of Antimicrobial Resistance Group

❮ Previous
Next ❯

Citations

Jul 25, 2007·Antimicrobial Agents and Chemotherapy·Federico PerezRobert A Bonomo
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Jan 17, 2008·Drugs·Jacob Gilad, Yehuda Carmeli
Mar 17, 2007·Scandinavian Journal of Infectious Diseases·Alex P BetrosianGeorge Georgiadis
Aug 28, 2015·Journal of Research in Pharmacy Practice·Mandana Izadpanah, Hossein Khalili
Dec 7, 2010·International Journal of Antimicrobial Agents·Ioannis K NeonakisEfthimia Petinaki
Apr 23, 2013·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Haiqing ChuJingbo Zhang
Dec 21, 2007·The Korean journal of laboratory medicine·Heungsup SungMi Na Kim
Jan 1, 2014·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Vu Dang HoangHue Minh Thi Nguyen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.